The Trump administration announced that Boston-based drugmaker EMD Serono will lower the price of one of its leading fertility drugs as part of a push to make in vitro fertilization (IVF) more ...

Merck KGaA’s U.S. arm EMD Serono is joining President Donald Trump’s most-favored nation drug pricing push with an agreement to sell its fertility therapies at a sharp discount through the ...

President Donald Trump made an announcement Thursday from the Oval Office that EMD Serono will reduce the cost of fertility medication in effort to help make IVF more affordable. Watch Trump’s remarks ...

EMD Serono's agreement with the US government aims to expand IVF therapy access for 10 million women, offering significant discounts on its portfolio. The company will participate in the TrumpRx.gov ...

Patients will have access to an expanded network from early 2026 and all EMD Serono’s fertility medications. Credit: MidoSemsem/Shutterstock.com. Merck’s healthcare division in Canada and the US, EMD ...

President Donald Trump on Thursday announced efforts to expand access to in vitro fertilization (IVF) by making such treatments more affordable. The move includes two priorities: lowering drug prices ...

Additionally, EMD Serono has secured an agreement with the U.S. Secretary of Commerce to exclude its pharmaceutical products and ingredients from Section 232 tariffs, contingent on the company ...

BOSTON, October 16, 2025--(BUSINESS WIRE)--EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, and President Donald J. Trump’s administration, today ...

President Donald Trump on Thursday announced an agreement to sell common fertility drugs at steeply reduced prices on TrumpRx, a direct-to-consumer drug platform the White House plans to launch in ...

Pfäffikon/Switzerland, 18/07/2025: Strong Polish local retailers such as Grupa Eurocash (Delikatesy Centrum, Lewiatan, Duży Ben, Eurocash Sieci Partnerskie (abc, groszek, Euro sklep), Partnerski ...

Cohort analyses from the WILLOW study reveal clear proof of concept in patients with CLE and SLE with active lupus rash, showing clinically meaningful improvement in disease activity at Week 16 ...